Tonix Pharmaceuticals Announced The Isolation And Functional Characterization Of The Two Mirror-image Isomers Of Racemic Tianeptine, Marketed As Major Depressive Disorder Treatment Outside The U.S.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced the isolation and functional characterization of two isomers of racemic tianeptine, with the (S)-isomer, TNX-4300 (estianeptine), showing potential for treating MDD, bipolar disorder, Alzheimer's, and Parkinson's disease. The company has begun preclinical development of TNX-4300.
May 23, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' discovery of the (S)-isomer of tianeptine and initiation of preclinical development for TNX-4300 could positively impact the company's stock price.
The discovery of the (S)-isomer of tianeptine and the initiation of preclinical development for TNX-4300 as a potential treatment for multiple neurological disorders could lead to increased investor interest and a positive impact on Tonix Pharmaceuticals' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100